Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alberto Zambelli

Showing results (131-140 of 162) with videos related to

Pageof 17
Sort By:
Cancer Treatment Reviews|August 29, 2024
Parp-inhibitors in the therapeutic landscape of breast cancer patients with BRCA1 and BRCA2 pathogenic germline variants: An Italian consensus paper and critical reviewAlberto Zambelli, Laura Cortesi, Mariangela Gaudio, et al.
Breast (Edinburgh, Scotland)|August 10, 2018
T-DM1 and brain metastases: Clinical outcome in HER2-positive metastatic breast cancerAlessandra Fabi, Daniele Alesini, Enrichetta Valle, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 26, 2026
Role of ctDNA in predicting the outcome of patients with hormone receptor-positive, HER2-negative advanced breast cancer treated with first-line ribociclib and letrozole: BioItaLEE trialGiampaolo Bianchini, Luca Malorni, Roberta Caputo, et al.
NPJ Breast Cancer|May 6, 2021
PONDx: real-life utilization and decision impact of the 21-gene assay on clinical practice in ItalyFrancesco Cognetti, Riccardo Masetti, Alessandra Fabi, et al.
European Journal of Cancer (Oxford, England : 1990)|May 16, 2022
Persistence of long-term COVID-19 sequelae in patients with cancer: An analysis from the OnCovid registryAlessio Cortellini, Ramon Salazar, Alessandra Gennari, et al.
Tumori|September 15, 2025
The use of bone-modifying agents in early breast cancer: AIOM Guidelines update and perspectivesAlberto Zambelli, Riccardo Gerosa, Michela Cinquini, et al.
Oncotarget|January 8, 2019
Correction 2: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA studyMarina Cazzaniga, Claudio Verusio, Mariangela Ciccarese, et al.
Critical Reviews in Oncology/Hematology|June 8, 2025
The evolving landscape of hormone receptor-positive/HER2-negative metastatic breast cancer (EVOLVE): An Italian Delphi consensus reportFederica Miglietta, Maria Grazia Razeti, Aldo Caltavituro, et al.
NPJ Breast Cancer|April 17, 2023
Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitorsEmma Zattarin, Daniele Presti, Luigi Mariani, et al.
Oncotarget|October 24, 2018
Correction: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA studyMarina Cazzaniga, Claudio Verusio, Mariangela Ciccarese, et al.
Pageof 17

Showing results (131-140 of 162) with videos related to

Sort By:
Pageof 17
Cancer Treatment Reviews|August 29, 2024
Parp-inhibitors in the therapeutic landscape of breast cancer patients with BRCA1 and BRCA2 pathogenic germline variants: An Italian consensus paper and critical reviewAlberto Zambelli, Laura Cortesi, Mariangela Gaudio, et al.
Breast (Edinburgh, Scotland)|August 10, 2018
T-DM1 and brain metastases: Clinical outcome in HER2-positive metastatic breast cancerAlessandra Fabi, Daniele Alesini, Enrichetta Valle, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 26, 2026
Role of ctDNA in predicting the outcome of patients with hormone receptor-positive, HER2-negative advanced breast cancer treated with first-line ribociclib and letrozole: BioItaLEE trialGiampaolo Bianchini, Luca Malorni, Roberta Caputo, et al.
NPJ Breast Cancer|May 6, 2021
PONDx: real-life utilization and decision impact of the 21-gene assay on clinical practice in ItalyFrancesco Cognetti, Riccardo Masetti, Alessandra Fabi, et al.
European Journal of Cancer (Oxford, England : 1990)|May 16, 2022
Persistence of long-term COVID-19 sequelae in patients with cancer: An analysis from the OnCovid registryAlessio Cortellini, Ramon Salazar, Alessandra Gennari, et al.
Tumori|September 15, 2025
The use of bone-modifying agents in early breast cancer: AIOM Guidelines update and perspectivesAlberto Zambelli, Riccardo Gerosa, Michela Cinquini, et al.
Oncotarget|January 8, 2019
Correction 2: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA studyMarina Cazzaniga, Claudio Verusio, Mariangela Ciccarese, et al.
Critical Reviews in Oncology/Hematology|June 8, 2025
The evolving landscape of hormone receptor-positive/HER2-negative metastatic breast cancer (EVOLVE): An Italian Delphi consensus reportFederica Miglietta, Maria Grazia Razeti, Aldo Caltavituro, et al.
NPJ Breast Cancer|April 17, 2023
Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitorsEmma Zattarin, Daniele Presti, Luigi Mariani, et al.
Oncotarget|October 24, 2018
Correction: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA studyMarina Cazzaniga, Claudio Verusio, Mariangela Ciccarese, et al.
Pageof 17